Biotechnology company Immutep (ASX:IMM) has received the grant of a new patent from the United States Patent Office for eftilagimod alpha in cancer.
This new patent provides intellectual property protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent.
The granted patent claims support the application of efti in Immutep’s ongoing clinical trial in metastatic breast cancer.
The patent will expire on 3 October 2028.
Shares in Immutep (ASX:IMM) closed 6.25 per cent higher to 3.4 cents yesterday.